drugset / Trial / NCT05504694
Ofatumumab in AQP4-IgG Seropositive NMOSD
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, multicentre prospective pilot study to assess the efficacy and safety of ofatumumab in patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) in China.
Timeline
- Start
- 2022-06-28
- Primary completion
- 2026-04-30
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ofatumumab | Monoclonal antibody | 20 mg | Subcutaneous |